| capecitabine / Generic mfg. |
NCT00635323: Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma |
|
|
| Completed | 2 | 73 | RoW | Irinotecan plus capecitabine | Pfizer | Carcinoma, Hepatocellular | | 05/05 | | |
NCT02013830: A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer |
|
|
| Completed | 2 | 45 | RoW | bevacizumab [Avastin], capecitabine [Xeloda] | Hoffmann-La Roche | Liver Cancer | 03/08 | 03/08 | | |
NCT00483405: Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer |
|
|
| Completed | 2 | 33 | US | cetuximab, Erbitux, capecitabine, Xeloda, oxaliplatin, Eloxatin | UNC Lineberger Comprehensive Cancer Center, Sanofi, Roche Pharma AG, Bristol-Myers Squibb, National Center for Research Resources (NCRR), National Cancer Institute (NCI) | Liver Cancer | 02/10 | 12/10 | | |
|
PACOX, NCT02089633: Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC |
|
|
| Completed | 2 | 17 | RoW | PACOX, PEG-BCT-100, Xeloda, Eloxatin | Bio-Cancer Treatment International Limited, The University of Hong Kong | Hepatocellular Carcinoma | 09/16 | 10/16 | | |
NCT00076609: Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma |
|
|
| Completed | 1/2 | 31 | US, RoW | PHY906, capecitabine | PhytoCeutica | Hepatocellular Carcinoma, Liver Cancer | | | | |
